Ozempic maker Novo Nordisk sues US rival over ‘materially misleading’ ads

Novo Nordisk is suing US rival Eli Lilly in a New Jersey federal district court over false and materially misleading advertisements. The Danish pharmaceutical company alleges that Eli Lilly intentionally utilized outdated studies to make its weight-loss and anti-diabetes treatments, Zepbound and Mounjaro, appear more effective. Novo Nordisk claims Lilly compared its own highest doses against lower doses of Novo Nordisk medicines to falsely suggest significantly greater weight loss performance in its marketing campaigns.